Drug
daratumumab and hyaluronidase-fihj (human recombinant)
Marketed as DARZALEX FASPRO.
Generic name
daratumumab and hyaluronidase-fihj (human recombinant)
Brand names
DARZALEX FASPRO
First FDA approval
2020-05-01
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| BLA761145 | DARZALEX FASPRO | 2020-05-01 | JANSSEN BIOTECH |
Manufacturers
JANSSEN BIOTECH
Frequently asked questions
When was daratumumab and hyaluronidase-fihj (human recombinant) FDA approved?
Earliest FDA approval on record: 2020-05-01.
What brand names are sold as daratumumab and hyaluronidase-fihj (human recombinant)?
DARZALEX FASPRO.
Sources
Appeal a daratumumab and hyaluronidase-fihj (human recombinant) denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com